Introduction
Induction of broadly neutralizing antibodies that inactivate the virus and prevent infection is currently part of the regular strategy to design a prophylactic vaccine against HIV-1. The ability of such antibodies to provide protection relies on their variable domains that confer antigen specificity and affinity. In contrast, the heavy chain constant (C H )-domains are generally thought as passive entities. IgG can also establish a network with other components of the immune system through its Fc portion, in addition to directly binding and neutralizing its targets. Thus, the antibody appears as a bi-functional molecule with regard to its binding and effector functions conferred by its variable and constant domains.
One of the most important Fc gamma receptor (FcgR)mediated activities is the mechanism of antibodydependent cellular cytotoxicity (ADCC) that involves components of both the innate and the adaptive immune system. In this mechanism, the Fc-antibody fragment binds to FcgRs on effector cells [natural killer (NK) cells, macrophages, neutrophils, or gamma/delta T cells], and the variable fragment binds to its specific epitope on the target cell surface, resulting in lysis of the antigenexpressing cells. ADCC is a well documented antiviral mechanism that controls viral infection, including HIV-1, by lysis of HIV-1-infected cells (reviewed in [1] [2] [3] [4] [5] ).
ADCC has been first attributed to nonneutralizing HIV-1 envelope-specific antibodies that are early induced in infection (reviewed in [6] ). However, both neutralizing and nonneutralizing antibodies specific for various epitopes in gp120 and gp41 can also mediate ADCC, including the neutralizing gp120-specific 2G12 and b12 IgGs ( [2, [7] [8] [9] [10] ). Accordingly, when the Fc region of 2G12 is mutated to impair its ability to bind FcgR, the resultant mutated antibody loses its ability to protect nonhuman primates (NHPs) against a simian-human immunodeficiency virus (SHIV) challenge after passive administration, in contrast to the native 2G12 that is fully protective ( [9] ).
Concerning gp41, the Cluster II gp41-specific IgG 98.6 is the best-known IgG triggering ADCC ( [11] ). Cluster II antibodies react with the membrane proximal external region (MPER) of gp41, and similarly to 98.6, are largely nonneutralizing except for 2F5 and 4E10 IgGs (reviewed in [12] ). 2F5 is a broadly neutralizing anti-HIV-1 IgG (reviewed in [1] ) isolated from sera of naturally asymptomatic infected individuals [13] . It recognizes the well conserved hexapeptide ELDKWA, the central region of the larger NEQELLELDKWASLWN sequence of the MPER [13, 14] . The ability of 2F5 to provide sterile protection to mucosal SHIV infection has often been studied in the NHP model (reviewed in [15, 16] ). It showed a positive correlation between the in vitro neutralization and in vivo protection, but the potential of 2F5 to trigger ADCC has not been evaluated.
Here, we investigated whether 2F5 could elicit ADCC of CD4 þ T-lymphocyte cell lines either infected with R5tropic HIV-1, stably expressing HIV envelope, or coated with MPER-derived peptides. Effectors were either human primary monocytes or the monocyte cell line THP1. We found that 2F5 induced an efficient ADCC in these systems. This ADCC is strictly dependent on 2F5 binding to gp41 ELDKWA on the target cell and to FcgRI (CD64) on the effector cell.
Materials and methods
Monoclonal antibodies, peptide, and recombinant proteins 2F5 has been previously described [13] . 2G12 and 98.6 were obtained from AIDS Research and Reference Reagent Program, NIH. Peptide P1 (aa 680-685 from HXB2 HIV-1) [17] was chemically synthesized (purity > 95%) by Eurogentec (Belgium).
The recombinant soluble gp160 was a chimeric protein composed of gp120 and gp41 derived from MN and LAI strains, respectively, produced from vaccinia virusinfected BHK21 cells (Aventis Pasteur, Marcy l'Etoile, France) [18] . Gp120 (LAI) was obtained from the AIDS Research and Reference Reagent Program, NIH.
Cells and viruses
NKr-CEM expressing CCR5, THP1, HIV-1 JR-CSF (clade B, R5-tropic) were obtained from the AIDS Research and Reference Reagent Program, NIH. HIV-1 JR-CSF was amplified as described [19] . CEM-Env213 cells stably expressing HIVenvelope of (X4 tropic clade B) HIV-1 strain 213 [20] was cultured as previously described [20] . Monocytes were purified from healthy donor peripheral blood mononuclear cells (PBMC) by negative selection using human monocyte enrichment kits (StemCell Technologies Inc., France). Resulting monocytes were FcgRIII negative (not shown).
HIV-infected NKr-CEM were obtained by infecting NKr-CEM with 1.5 mg p24 of HIV1 JR-CSF/1 Â 10 6 cells. Cell infection was evaluated by intracellular p24 staining as described [19] , and HIV-1 envelope expression on the infected cell surface was monitored from day 5 to 14 postinfection using 2F5, and 98.6, and analyzed by flow cytometry as described [19] (not shown).
NKr-CEM were coated with HIV envelope subunits as described [21] . Briefly, 1 Â 10 6 cells were incubated with P1 (5 mmol/l), gp160 (3 mg), or gp120 (3 mg) in 300 ml of RPMI 1640, 10% FCS (R10 media) for 1 h at room temperature, followed by two times washes in ice-cold R10.
Binding assays
For HIV-1 specific envelope mAb binding to target or effector cells, 2F5, 98.6, 2G12, or human isotype control at 10 or 1 mg/ml were incubated with 0.5 Â 10 6 appropriate cells in R10 for 1 h at 48C, followed by fluorescein isothiocyanate (FITC)-conjugated antihuman IgG (Jackson ImmunoResearch, West Grove, Pennsylvania, USA) at 10 mg/ml.
For FcgR detection on effector cells, 0.5 Â 10 6 cells, either monocytes, or THP1, in R10 were incubated with FcgR-specific mAb (mouse IgG1k; Pharmingen, Franklin Lakes, New Jersey, USA) at 10 and 1 mg/ml as indicated above.
When indicated, human irrelevant IgG, Fcg RI-or RIIspecific mAb was added in 10-fold excess to effector cells prior to addition of envelope-specific mAbs at 1 mg/ml. Cells stained with matched isotype control Abs served as negative controls. Fluorescence profiles (10 000 events), gated as forward and side scatter on live cells, were recorded using a FACS Calibur and results were analyzed using the CellQuest Pro software as described [19] . Assays were performed in duplicate.
Antibody-dependent cellular cytotoxicity ADCC was performed using a rapid fluorescent-based assay as described [21] . Briefly, target cells at 3 Â 10 6 cells/ ml were dually stained with the cytosolic dye 5-(and -6-) carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, Oregon, USA) at 1 mmol/l and the membrane dye PKH-26 (Sigma, St Louis, Missouri, USA) at 1 mmol/l for 5 min at 378C. After staining, target cells were incubated with the antibodies (2F5, 2G12, or 98.6 IgGs) for 30 min at room temperature. Effector cells, human purified monocytes or THP1, were then added at an Effector:Target (E:T) ratio of 10 : 1. When indicated, cells were incubated with irrelevant IgG for 15 min prior to their addition in the ADCC reaction. Then, cell co-cultures were centrifuged for 1 min at 1000 rpm and incubated for 4 h at 378C. When infected cells were used as targets, they were fixed with 4% paraformaldehyde. Fluorescence profiles of the cell cocultures were immediately acquired using a Beckman Coulter FC500 instrument. Data analysis was performed using Cytomics RXP software. Flow cytometry dot plot of dual-stained target cells incubated in the same conditions as the effector-target co-cultures is used to set the gate of living double positive target cells, in which the cell membrane is still intact. ADCC is calculated as follows:
(% of PKH-26 high CFSE negative cells)/(% of PKH-26 high CFSE negative cells) þ (% of PKH-26 high CFSE high cells) Â 100. When HIV-infected cells were used as target, the ADCC was corrected by the actual amount of HIV-1-infected cells present at the beginning of the assay, as determined by intracellular p24 labeling (as indicated above). Percentage of ADCC lysis is estimated as the difference in amount killing in presence and absence of a given antibody.
Results and discussion
To investigate whether 2F5 could mediate ADCC, we comparatively used several systems. Effector cells were either purified human monocytes or the human THP1 monocytic cells. As target cells, we first used the CD4 þ Tcell line natural killer resistant-CEM (NKr-CEM) either coated with the peptide P1, an extended MPER peptide [17] , or with a recombinant gp160. Alternatively, NKr-CEM stably expressed a functional X4 tropic, clade B HIV envelope gp41 and gp120 (referred here as CEM-Env213, [20] ) or were infected with the HIV-1 strain JR-CSF (clade B, R5). P1 (aa 649-684) covers the entire MPER and allows for HIV-1 binding to its mucosal receptor galactosyl ceramide (GalCer) and in turn mediates HIV-1 transcytosis across epithelial cells [17] and uptake by dendritic cells [22] . P1 encompasses the hexapeptide ELDKWA (aa 662-666), which serves as the target of the 2F5 IgG, and a W-rich hydrophobic C-terminal domain [23] . Importantly, 2F5 IgG has a higher affinity for P1 as compared to the ELDKWA peptide and in addition, the affinity of 2F5 for P1 is increased by a factor of 10 when P1 is presented in a lipidic context, as it is at the viral surface in vivo [23] .
2F5 binds to effector cells
The FcgR binding of 2F5 to effector cells such as human purified monocytes and THP1 cells was evaluated by flow cytometry ( Table 1) . Incubation of monocytes with 10 or 2F5-IgG elicits potent gp41-specific ADCC Tudor and Bomsel 753 IgGs were incubated with purified monocytes or THP1 as effector cells, or P1-coated, gp160-coated cells, CEM-Env213, or JR-CSF-infected cells as target cells for 30 min at 48C. For THP1 binding, cells were also preincubated for 15 min with various FcgRI and FcgRII-blocking antibodies prior to incubation with HIV-1 specific envelope IgG. Specific binding was analyzed by flow cytometry as indicated in Materials and methods section.
Values represent percentage of cells that stain positive for each antibody AESD. One representative experiment out of three is shown. n.t., not tested; NKr-CEM, natural killer resistant-CEM. 1 mg/ml of antibody resulted in 16% (AE0.95) and 14% (AE1.1) of 2F5-specific binding, respectively, similar to 98.6 and 2G12, two IgGs used below as positive control for ADCC. Comparatively, binding of all three IgGs to THP1 was more efficient, with 100% of cell-specific binding at 1 mg/ml, and is concentration dependent (not shown).
Three FcgRs have been described in the human: FcgRI (CD64), FcgRII (CD32), and FcgRIII (CD16). Only two of them, FcgRI for the monocytes, and FcgRIII for the NK cells, participate in ADCC [2] . The level of FcgRI and FcgRII expression was lower on human monocytes than on THP1 cells. Thus 25.20% (AE2.83) and 3.95% (AE0.65) of monocytes were positive for FcgRI and RII, respectively as compared with 94.42% (AE0.60) and 90.76% (AE3.04) for THP1. Neither monocytes nor THP1 cells express FcgRIII (CD16; 3.11% AE 1.71 and 5.17% AE 0.85, respectively). 2F5 binding to effector cells was significantly reduced in the presence of a 10-fold excess of a FcgRI mAb (binding reduction of 37% AE 3.83; P ¼ 0.02), but not FcgRII-specific antibody 2F5-IgG elicits potent gp41-specific ADCC Tudor and Bomsel 755 (binding reduction of 14% AE 3.47; P > 0.05). These results indicate that 2F5 used FcgRI to bind to THP1 effector cells.
2F5 binds to target cells
Next, the ability of 2F5 and of 2G12 and 98.6 mAbs to bind to target cells was evaluated by flow cytometry (Table 1) . Ninety percent (AE1.95) of the P1-coated NKr-CEM stained positive for 2F5, in contrast to gp120-specific 2G12, as expected. Instead 2G12, and gp41-specific 98.6 bound 100% of gp160-coated NKr-CEM, whereas 2F5 stained 79% (AE1.30) of these cells.
2F5 bound also to HIV-1-infected NKr-CEM cells but weakly as already shown [24, 25] . Similar 2F5 binding was observed for CEM-213env cells ( Table 1 ). It suggests that on the surface of a cell expressing HIVenvelope as a spike, the 2F5 epitope is expressed at lower level/density, or is less accessible [26] as compared to peptide-coated cells. We, therefore, comparatively evaluated ADCC of these various target cells.
2F5 triggers antibody-dependent cellular cytotoxicity
Antibody-dependent cellular cytotoxicity of P1-coated natural killer resistant-CEM cells The capacity of 2F5 to trigger the lysis of target cells via ADCC was monitored using a recently developed fluorimetric assay based on differential membrane and cytosol labeling of the target cells. As effector cells are not labeled, lyzed cells (membrane labeled, but having lost their cytosolic labeling) can easily be differentiated from healthy target (membrane and cytosol labeled), and nonfluorescent effector cells. As shown in Fig. 1a , 2F5 bound to human THP1 cells (upper panel) or monocytes (middle panel) triggers an efficient ADCC of P1-coated NKr-CEM. ADCC efficiency induced by 0.1 or 0.5 mg/ml of 2F5 with both effector cell types was similar. Importantly, the concentration required for ADCC is around 100 times lower than that required for neutralization of HIV-1 infection using either PBMCs or HIV envelope expressing reporter cell lines [27] , with 90% inhibitory concentration (IC 90 ) ranging between 30 and 50 mg/ml. ADCC elicited by 2F5 was reduced by 42.24% (AE0.35) when the mAb was preincubated with the peptide epitope ELDKWA, whereas preincubation with QAR-ILAV, an irrelevant epitope located on the gp41 leucine zipper, had no effect (Fig. 1f ). This partial reversion is likely due to the higher affinity of 2F5 for P1 as compared to ELDKWA [14, 23] .
A low background lysis was observed in the presence of normal serum IgG demonstrating the specificity of the mechanism (Fig. 1a, right panel) . In addition, when monocytes or THP1 effector cells were precoated with an excess (50 or 100 mg) of normal serum IgG, ADCC induced by 2F5 using monocytes as effectors was reduced by 46% (AE0.45) and 33% (AE0.89) for 0.5 and 0.1 mg/ml of 2F5, respectively, whereas ADCC mediated by THP1 cells was decreased up to 80% (AE0.25) by 100 mg of IgG.
Finally, when NKr-CEM were coated with gp120, only gp120-specific 2G12 elicited ADCC, whereas 2F5 was inefficient, showing that 2F5-mediated ADCC is specific for gp41 exposed on the target cell (Fig. 1b) .
Altogether, these results show that 2F5 specifically elicits ADCC of P1-coated target cells.
Antibody-dependent cellular cytotoxicity of gp160coated natural killer resistant-CEM cells Next, 2F5-mediated ADCC of gp160-coated NKr-CEM was evaluated in the presence of THP1 cells (Fig. 1c ). Gp120-specific 2G12 and gp41-specifc 98.6 mAbs were used as positive controls.
2F5 triggered the ADCC of gp160-coated NKr-CEM, though with a lower efficiency as compared to 98.6 and 2G12, in agreement with the lower binding efficiency of 2F5 to gp160-coated cells as compared to 2G12 and 98.6 ( Table 1 ) and suggests that the 2F5-epitope may not be properly exposed on gp160.
Antibody-dependent cellular cytotoxicity of CEM stably expressing an X4 HIV-1 envelope spike To overcome the issue of the proper exposure of the 2F5 epitope encountered with the HIV-1 envelope glycoprotein gp160 coated target cells, including accessibility and/or three-dimensional structure, we next evaluated ADCC of CEM-Env213 stably expressing an X4 tropic, clade B HIV-1 envelope forming a spike, as it is the case on HIV-1-infected cells [20] . These cells have been used in the past for easy ADCC monitoring. Using THP1 as effector cells, 2F5 induced up to 24.37% (AE0.51) of specific CEM-env213 ADCC for 0.1 mg/ml of antibody in a specific manner (Fig. 1d ). Indeed, ADCC was completely abolished when 2F5 was preincubated with ELDKWA to block its binding to the target cell (Fig. 1f) . In contrast, QARILAV had no effect (Fig. 1f ).
Antibody-dependent cellular cytotoxicity of natural killer resistant-CEM cells infected with R5 HIV-1 JR-CSF Finally, we evaluated ADCC elicited by 2F5 of NKr-CEM infected by JR-CSF, an R5-tropic HIV-1 isolate. As the viruses initially transmitted are generally R5-tropic rather than X4, this model tends to mimic the cells that are rapidly infected upon transmission. NKr-CEM efficiently replicates HIV-1 JR-CSF strain, with around 30% cells infected after 5 days in the presence of 1.5 mg of p24/million cells. However, infection results also in cell apoptosis. Apoptotic cells cannot be differentiated from cell lyzed by ADCC in the assays used in this study, so that the background of target cell lysis is much higher than that observed with CEM-env213. Nevertheless, despite this technical issue, 2F5 induced a specific ADCC mediated by THP1 reaching 24.17% (AE1.18) lysis of the infected cells for 0.1 mg/ml of 2F5 (Fig. 1e ). Furthermore, ADCC elicited by 2F5 was specific, as it was abolished by a 100fold excess of irrelevant human IgG (specific ADCC of 0%). Strikingly, 2F5 at 100 ng/ml concentration triggered ADCC of R5-tropic JR-CSF-infected cells, and X4tropic envelope expressing CEM-Env213 to a similar extent despite the tropism difference of the envelope (R5 vs. X4). It confirms at the functional level that the epitope recognized by 2F5 is accessible on the virus spike, as shown by structural analyses [28, 29] . In contrast, 98.6, recognizing a less accessible epitope on gp41 hidden in the virus spike by the gp120 subunit [28] , induced 50% less ADCC of HIV-1-infected cells as compared to CEM-Env213. These data emphasize the importance of epitope accessibility, due to potential spike conformation and concentration, as well as antibody cognate epitope accessibility in determining the sensitivity of an assay. In any case, the surface accessible epitope CEM-Env213 offers a good experimental ADCC-target cell model rather than infected cells, an experimental system more difficult to handle.
Altogether, the present study demonstrates for the first time that in vitro, 2F5 can trigger ADCC, not only of HIV envelope subunit coated T cells, but also of CEM-Env213 expressing stably an X4 tropic, and of R5 tropic HIV-1infected cells.
Conclusion
HIV-1 is mainly transmitted at the mucosal sites, after rapid HIV-1 translocation across surface epithelium by transcytosis or uptake by dendritic cells. In turn, in the NHP model, the virus quickly infects a small founder population of cells that can locally expand and migrate to the lymphatic tissues to fuel a systemic infection (reviewed in [30] ). Therefore, the window to block mucosal HIV-1 entry is restricted to a few hours for transcytosis blockade, prevention of HIV-1 uptake by dendritic cell, and transfer to local T cells, and to a few days for containment or eradication of the small HIV-1 founder cell population.
2F5 has mainly been considered for its broadly neutralizing activity of HIV1-containing blood-derived cells [31] . However, at the mucosal level, it now appears that 2F5 could work as a potent antiviral. Hence, 2F5 has been shown to block in vitro the initial steps of mucosal HIV-1 entry that do not involve infection, namely, blockade of cell-cell transmission across infectious synapses [32] , transcytosis [33, 34] , and HIV-1 uptake by dendritic cells ( [22] , also reviewed by [35] ). Our present results now show that by triggering significant ADCC of R5-tropic HIV-1-infected cells, 2F5 has the potential to eliminate the initial HIV-1-infected popu-lation upon mucosal HIV-1 transmission and, thus, to block the expansion of the founder seed stocks of virusinfected cells resulting in systemic infection.
The nanogram quantities required to elicit ADCC (this study) or block transcytosis ( [19] ) in vitro are at least 100 times lower than those required for the complex process antibody-dependent cell-mediated virus inhibition (ADCVI) [16] . ADCVI is closely related to ADCC, as it relies on interactions between FcR-bearing effector cells, the antibody, and an infected target cell. However, ADCVI measures inhibition of HIV release by the infected target cells rather than cell lysis. Such HIV release inhibition may result from a panoply of both cytotoxic and noncytotoxic mechanisms [36] that may be diversely affected by 2F5. In contrast, when focusing only on the ADCC activity, the present study shows that 2F5 induces a potent ADCC. Results show a striking difference between ADCC and ADCVI potential of 2F5.
Dimerization of 2G12 has recently been shown [7] to elicit ADCC of X4-tropic envelope-expressing cells to a similar extent as 2F5. 2F5 does not require such an increase in affinity provided by dimerization and appears naturally active most likely because 2F5 affinity for its cognate epitope in a lipidic context, namely on P1 coated cells, or on CEM-env213 or on HV-1-infected cells, is enhanced by 10-fold as compared to the affinity of 2F5 determined by ELISA as we have shown earlier [23] . In the present study, the ADCC mediated by 2F5 we report using monocytes as effector cells is mediated by FcgRI. Other neutralizing or nonneutralizing Abs have also been shown to trigger an FcgRI-dependent ADCC [2, [37] [38] [39] . FcgRI appears to have additional role in gp41specific IgG antiviral activities. Hence, strikingly, FcgRI has been recently reported to also increase the neutralizing activity of 2F5 and other gp41 MPER-specific Abs, but not gp120-specific ones, when expressed on the TZM-bl target cells [40] . Furthermore, when using macrophages, Holl et al. [41] reported that neutralization of HIV-1 macrophage infection by 2F5 is dependent on FcgRI. Together with our present results, these studies overall support a critical role of Fc-FcgRI interactions in the antiviral functions of anti-HIV Abs, which are likely to be helpful in preventing or modulating the infection.
Importantly, in vivo, ADCC does not require prestimulation of the adaptive immune system and could, therefore, act immediately against the incoming virus, providing the antibody is present in situ, or given by passive immunotherapy, for example. Together with the recently described ADCC activity of the gp120-specific broadly neutralizing IgG 2G12, the present results widen our understanding of the mechanism by which passive therapy could help at counteracting mucosal transmission of HIV-1 [8, 16] , using either macrophages or NK cells as effectors.
The antiviral activity of 2F5 now appears mediated not only by neutralization of free virions (reviewed in [15] , [16] ), or by blocking synapse formation [32, 42] , and in turn transcytosis [32] , or by transfer to T cells [22, 35, 43] , but also by binding to virus-specific proteins expressed on the surface of infected cells and by the recruitment of Fcmediated effector functions, thereby eliciting ADCC, as we demonstrated here.
The broad reactivity of 2F5 against different HIV-1 strains and its ability to trigger HIV-1-specific ADCC responses may be an important correlate for protection against cell-associated virus in vaccine development. Accordingly, we have recently shown that in gp41vaccinated monkeys challenged by the vaginal route with infectious SHIV that remain uninfected despite 13 low dose challenges, one correlate to protection was the presence of mucosal IgG specific for gp41 MPER with in vitro ADCC activities [44] . Along this line, efficient vaccine may rather aim at inducing broad and potent neutralizing anti-HIV-1 Abs, but also envelope-specific IgGs able to induce ADCC. Of note, ADCC inducing IgGs usually appear before neutralizing one in the development of the immune response. Such IgGs might eliminate HIV-1-bound target cells, or the initially infected cells, prior to establishment of a productive infection.
